These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12480514)

  • 21. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
    Li HY; Oh YS; Choi JW; Jung JY; Jun HS
    Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression.
    Han DC; Isono M; Chen S; Casaretto A; Hong SW; Wolf G; Ziyadeh FN
    Kidney Int; 2001 Apr; 59(4):1315-23. PubMed ID: 11260392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells.
    Isono M; Chen S; Hong SW; Iglesias-de la Cruz MC; Ziyadeh FN
    Biochem Biophys Res Commun; 2002 Sep; 296(5):1356-65. PubMed ID: 12207925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney.
    Lee EA; Seo JY; Jiang Z; Yu MR; Kwon MK; Ha H; Lee HB
    Kidney Int; 2005 May; 67(5):1762-71. PubMed ID: 15840023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator.
    Ziyadeh FN
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S55-7. PubMed ID: 14684674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of mesangial expansion in the pathogenesis of diabetic nephropathy.
    Dalla Vestra M; Saller A; Mauer M; Fioretto P
    J Nephrol; 2001; 14 Suppl 4():S51-7. PubMed ID: 11798146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The lack of cyclin kinase inhibitor p27(Kip1) ameliorates progression of diabetic nephropathy.
    Awazu M; Omori S; Ishikura K; Hida M; Fujita H
    J Am Soc Nephrol; 2003 Mar; 14(3):699-708. PubMed ID: 12595506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse.
    Cohen MP; Masson N; Hud E; Ziyadeh F; Han DC; Clements RS
    Exp Nephrol; 2000; 8(3):135-43. PubMed ID: 10810230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glomerular extracellular matrices in rat diabetic glomerulopathy by scanning electron microscopy.
    Makino H; Yamasaki Y; Hironaka K; Ota Z
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1992; 62(1):19-24. PubMed ID: 1352071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
    Daniel C; Schaub K; Amann K; Lawler J; Hugo C
    Diabetes; 2007 Dec; 56(12):2982-9. PubMed ID: 17878288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The renal TGF-beta system in the db/db mouse model of diabetic nephropathy.
    Cohen MP; Sharma K; Guo J; Eltayeb BO; Ziyadeh FN
    Exp Nephrol; 1998; 6(3):226-33. PubMed ID: 9639038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.
    Ziyadeh FN
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S38-41. PubMed ID: 18842317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice.
    Diani AR; Peterson T; Sawada G; Jodelis K; Wyse BM; Gilchrist BJ; Hearron AE; Chang AY
    Nephron; 1986; 42(1):72-7. PubMed ID: 3941752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice.
    Naito Y; Uchiyama K; Aoi W; Hasegawa G; Nakamura N; Yoshida N; Maoka T; Takahashi J; Yoshikawa T
    Biofactors; 2004; 20(1):49-59. PubMed ID: 15096660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glomerulopathy in spontaneously diabetic rat. Impact of glycemic control.
    Cohen AJ; McGill PD; Rossetti RG; Guberski DL; Like AA
    Diabetes; 1987 Aug; 36(8):944-51. PubMed ID: 3596062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.
    Ichinose K; Maeshima Y; Yamamoto Y; Kinomura M; Hirokoshi K; Kitayama H; Takazawa Y; Sugiyama H; Yamasaki Y; Agata N; Makino H
    Diabetes; 2006 May; 55(5):1232-42. PubMed ID: 16644677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic kidney disease in the db/db mouse.
    Sharma K; McCue P; Dunn SR
    Am J Physiol Renal Physiol; 2003 Jun; 284(6):F1138-44. PubMed ID: 12736165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic glomerulopathy in the uninephrectomized rat resists amelioration following islet transplantation.
    Steffes MW; Vernier RL; Brown DM; Basgen JM; Mauer SM
    Diabetologia; 1982 Oct; 23(4):347-53. PubMed ID: 6814977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.